Japan Cell and Gene Therapy Market Report, Share & Analysis 2026-2034

Market Overview

The Japan Cell and Gene Therapy Market size was valued at USD 814.2 Million in 2025, with a projected market size of USD 2,151.4 Million by 2034. The market is set to grow at a CAGR of 11.40% over the forecast period of 2026–2034. This robust growth is attributed to factors such as advancements in biotechnology, widespread adoption of novel therapies, government support, and a rapidly aging population. Increasing incidences of hereditary and chronic diseases, coupled with intensified research and development activities, further bolster market expansion.

How AI is Reshaping the Future of Japan Cell and Gene Therapy Market

• AI-powered data analytics is accelerating drug development cycles in Japan, enabling faster identification of viable cell and gene therapy candidates and reducing time to market by leveraging large-scale clinical data.
• Japanese government initiatives have supported AI integration in regenerative medicine, with partnerships between public agencies and research institutions fueling the adoption of smart, algorithm-based protocols in therapy validation.
• Leading companies are utilizing AI for personalized treatment pathways, enhancing patient stratification for gene editing or cell-based therapies, and increasing the likelihood of successful clinical outcomes.
• AI-driven platforms are streamlining manufacturing processes, ensuring higher consistency and quality control in cell product fabrication, thus reducing production costs for therapy providers.
• Recent collaborations, such as those by Terumo Blood and Cell Technologies and research foundations, are deploying AI to automate workflows for induced pluripotent stem (iPS) cell therapies, broadening access and scalability.
• AI is increasingly used for early detection of chronic and genetic disorders, integrating with live cell metabolic analyzers to provide ongoing monitoring of therapy effectiveness without clinical interruption.

Market Growth Factors

Advancements in biotechnology and regenerative medicine are pivotal drivers of the Japan cell and gene therapy market. The emergence and application of cutting-edge technologies like CRISPR and CAR-T enable precise genetic modifications and innovative treatments for diseases once thought untreatable. The report highlights regulatory structures such as the Act on the Safety of Regenerative Medicine’s accelerated approval process, encouraging faster commercialization and widespread deployment of advanced therapies. Notable examples include new drug approvals and the increasing focus on personalized medicine, reflecting how the country’s adoption of technological advancements is fueling market demand and broadening therapeutic portfolios.

The increasing incidence of chronic and hereditary diseases, combined with Japan’s aging population, intensifies the need for cell and gene therapies. The report states that high occurrences of cancer, cardiovascular disorders, and rare genetic conditions drive strong demand for curative solutions. Patients, especially those affected by diseases like cancer or genetic abnormalities, are seeking novel options as traditional therapies offer limited outcomes. The widespread demand is underscored by targeted investments in research and development and government-backed initiatives, advancing the availability of transformative and life-changing therapeutic alternatives throughout the country.

Robust government and industry investments, as well as academic collaborations, are expanding research, clinical studies, and therapy accessibility in Japan. Substantial funding and cooperative ventures enable the development and fast-tracking of innovative therapies. For example, partnerships between biotech companies, universities, and financial institutions result in a deepened pipeline of regenerative medicines and ensure Japan’s leading role in clinical trial activity. Real-world corporate news in the sector reveals ongoing investment agreements and technology exchanges, all supporting the constant evolution and strength of the cell and gene therapy marketplace.

Market Segmentation

Analysis by Therapy Type:

• Cell Therapy
• Stem Cell
• Non-Stem Cell
• Gene Therapy

Analysis by Indication:

• Cardiovascular Disease
• Oncology Disorder
• Genetic Disorder
• Infectious Disease
• Neurological Disorder
• Others

Analysis by Delivery Mode:

• In-Vivo
• Ex-Vivo

Analysis by End User:

• Hospitals
• Cancer Care Centers
• Pharmaceutical and Biotechnology Companies
• Others

Regional Analysis:

• Kanto Region
• Kansai/Kinki Region
• Central/ Chubu Region
• Kyushu-Okinawa Region
• Tohoku Region
• Chugoku Region
• Hokkaido Region
• Shikoku Region

Key Players

• Takeda Pharmaceutical
• Astellas Pharma
• Fujifilm Cellular Dynamics
• Novartis
• Bristol-Myers Squibb
• Gilead Sciences

Recent Developement & News

• September 2025: AGC, the parent company of AGC Biologics and MEDINET, finalized a partnership for the cell therapy CDMO business. AGC aims to leverage MEDINET's expertise with Japan-based start-ups and academia to prepare for the launch of cell therapy CDMO services at AGC Biologics’ Yokohama site, with part of the service beginning in 2025. The initiative is set to boost domestic expertise and service capacity in cell therapy production.
• July 2025: The National Cancer Center (Tokyo) and The University of Pennsylvania granted ARC Therapies Inc. patent rights to CCR4 CAR-T cell therapy targeting T-cell cancers, including adult T-cell leukemia/lymphoma (ATLL), which is prevalent in Japan. The agreement marks the beginning of ARC Therapies’ R&D efforts targeting both hematological and solid cancers, signaling Japan's leadership in oncology-focused cell therapies.
• June 2025: Teijin Limited announced a Memorandum of Understanding with Hilleman Laboratories (Singapore) to develop strategic international cooperation aimed at growing the cell and gene therapy industry's CDMO business. The collaboration focuses on manufacturing advancements and amplifies Japan’s role as a contract development and manufacturing hub for regenerative medicines.

Customization Note:

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302